SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: select one drug below

❑ **Rinvoq®** (upadacitinib)	❑ **Rinvoq® LQ** (upadacitinib)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

NOTE: The health plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

(Continued on next page)

❑ **Diagnosis: Moderate-to-Severe Rheumatoid Arthritis**
Dosing: Oral: Rinvoq®: 15 mg once daily

- ❑ Member is at least 18 years of age and have a diagnosis of rheumatoid arthritis (RA)
- ❑ Use in combination with other JAK inhibitors, biologic DMARDS, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended
- ❑ Trial and failure of **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

❑ **Diagnosis: Active Psoriatic Arthritis**			
Dosing: Oral: Rinvoq® or Rinvoq® LQ			
Patient Age	**Patient Weight**	**Rinvoq® LQ**	**Rinvoq®**
2 to < 18 years of age	10 kg to < 20 kg	3 mg (3 mL) twice daily	Not Recommended
	20 kg to < 30 kg	4 mg (4 mL) twice daily	Not Recommended
	> 30 kg	6 mg (6 mL) twice daily	15 mg once daily
≥ 18 years of age	N/A	N/A	15 mg once daily

- ❑ Member has a diagnosis of active psoriatic arthritis
- ❑ Member is 2 years of age or older
- ❑ Use in combination with other JAK inhibitors, biologic DMARDS, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended
- ❑ Trial and failure of **TWO (2)** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®	❑ Pyzchiva® syringe/vial **OR** Starjemza™ (Requires trial and failure of a preferred TNF-alpha inhibitor)

❑ **Diagnosis: Moderate-to-Severe Atopic Dermatitis**
Dosing: Oral: Rinvoq®: 15 mg once daily; may increase to 30 mg once daily if inadequate response

- ❑ Member is 12 years of age or older weighing at least 40kg
- ❑ Prior documented trial and failure of 30 days for each trial (or contraindication) of:
  - ❑ One (1) topical corticosteroid of medium to high potency (e.g., mometasone, fluocinolone) **OR**
  - ❑ One (1) topical calcineurin inhibitors (tacrolimus or pimecrolimus) **AND**
  - ❑ Trial and failure of Dupixent®

(Continued on next page)

❑ **Diagnosis: Moderate-to-Severe Ulcerative Colitis (UC)**
Dosing: Oral: Rinvoq®: Induction - 45 mg once daily for 8 weeks; Maintenance -15 mg once daily; may increase to 30 mg once daily in patients with refractory, severe, or extensive disease. Discontinue if an adequate response is not achieved with the 30 mg dose; use the lowest effective dose needed to maintain response.

- ❑ Member is at least 18 years of age and have a diagnosis of moderate to severe active ulcerative colitis
- ❑ Trial and failure of **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Pyzchiva® syringe/vial **OR** Starjemza™ (Requires trial and failure of a preferred TNF-alpha inhibitor)

- ❑ If TNF inhibitors are clinically inadvisable, member must try and fail at least one other systemic therapy for UC prior to use of Rinvoq
- ❑ Member is **NOT** receiving Rinvoq® in combination with other JAK inhibitors, biologic DMARDs, or potent immunomodulators such as azathioprine or cyclosporine is not recommended

❑ **Diagnosis: Moderate-to-Severe Active Crohn's Disease (CD)**
Dosing: Oral: Rinvoq®: Induction - 45 mg once daily for 12 weeks; Maintenance -15 mg once daily; may increase to 30 mg once daily in patients with refractory, severe, or extensive disease. Discontinue if an adequate response is not achieved with the 30 mg dose; use the lowest effective dose needed to maintain response

- ❑ Member is at least 18 years of age and have a diagnosis of moderate to severe active Crohn's disease
- ❑ Trial and failure of **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Pyzchiva® syringe/vial **OR** Starjemza™ (Requires trial and failure of a preferred TNF-alpha inhibitor)

- ❑ If TNF inhibitors are clinically inadvisable, member must try and fail at least one other systemic therapy for CD prior to use of Rinvoq
- ❑ Member is **NOT** receiving Rinvoq® in combination with other JAK inhibitors, biologic DMARDs, or potent immunomodulators such as azathioprine or cyclosporine is not recommended

(Continued on next page)

❑ **Diagnosis: Active Ankylosing Spondylitis**
Dosing: Oral: Rinvoq®: 15 mg once daily

- ❑ Member is at least 18 years of age and have a diagnosis of ankylosing spondylitis
- ❑ Trial and failure of **BOTH** of the **PREFERRED** drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

- ❑ Member is **NOT** receiving Rinvoq® in combination with other JAK inhibitors, biologic DMARDs, or potent immunomodulators such as azathioprine or cyclosporine is not recommended

❑ **Diagnosis: Active Non-Radiographic Axial Spondyloarthritis**
Dosing: Oral: Rinvoq®: 15 mg once daily

- ❑ Member is at least 18 years of age and have a diagnosis of Non-Radiographic Axial Spondyloarthritis
- ❑ Member is **NOT** receiving Rinvoq® in combination with other JAK inhibitors, biologic DMARDs, or potent immunomodulators such as azathioprine or cyclosporine is not recommended

❑ **Diagnosis: Polyarticular Juvenile Idiopathic Arthritis**

Dosing: Oral: Rinvoq® or Rinvoq® LQ

Patient Age	Patient Weight	Rinvoq® LQ	Rinvoq®
2 to < 18 years of age	10 kg to < 20 kg	3 mg (3 mL) twice daily	Not Recommended
	20 kg to < 30 kg	4 mg (4 mL) twice daily	Not Recommended
	> 30 kg	6 mg (6 mL) twice daily	15 mg once daily
≥ 18 years of age	N/A	N/A	15 mg once daily

- ❑ Member has a diagnosis of polyarticular juvenile idiopathic arthritis
- ❑ Member is 2 years of age or older
- ❑ Use in combination with other JAK inhibitors, biologic DMARDS, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended
- ❑ Trial and failure of **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

(Continued on next page)

❑ **Diagnosis: Giant Cell Arteritis**
Dosing: Oral: Rinvoq®: 15 mg once daily

- ❑ Member is 18 years of age or older
- ❑ Member has a diagnosis of giant cell arteritis
- ❑ Use in combination with other JAK inhibitors, biologic DMARDS, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended

Medication being provided by Specialty Pharmacy - PropriumRx

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee**: ~~10/17/2019; 11/18/2022;~~ **8/17/2023**
REVISED/UPDATED/REFORMATTED: ~~11/20/2019 3/1/2022; 3/16/2022; 4/25/2022; 6/6/2022; 8/22/2022; 11/22/2022; 12/23/2022; 4/21/2023; 6/20/2025, 9/10/2025; 12/16/2025; 1/21/2026, 2/24/2026;~~ **3/12/2026**